NCIt definition : A Fc-engineered immunoglobulin G1-kappa (IgG1k) monoclonal antibody targeting the
co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3), with potential
immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration,
tuparstobart targets and binds to human LAG-3 on tumor-infiltrating lymphocytes (TILs)
and blocks the interaction between LAG-3 and major histocompatibility complex class
II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor
cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC
II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against
tumor cells, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin
superfamily (IgSF), negatively regulates both proliferation and activation of T-cells.
Its expression on TILs is associated with tumor-mediated immune suppression.;
UNII : Z0A08C63DF;
CAS number : 2649466-03-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2649466-03-3
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : INCAGN 2385; INCAGN2385; INCAGN02385; INCAGN 02385;
Semantic type(s)